Oct122020UncategorizedCategory: UncategorizedBy Charlotte Maddalena12 October 2020 Author: Charlotte Maddalena Post navigationPreviousPrevious post:ORPHELIA announces the inclusion of the first patient in a clinical study evaluating Kimozo, its pediatric formulation of temozolomideNextNext post:Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog AZP-3601Related PostsSix new projects supported by our Foundation18 March 2024Four houses for the FAOMA call for projects18 March 2024ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024Seven new projects supported by our Foundation8 January 2024Newsletter December 202318 December 2023Orphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023
ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024
Orphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023